Moody’s Boosts Boston Scientific Debt Rating (BSX)

Photo of Paul Ausick
By Paul Ausick Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Ratings agency Moody’s has raised the debt rating of Boston Scientific Corp. (NYSE: BSX) from ‘Ba1’ to ‘Baa3’ with a stable outlook. The new rating applies to new senior unsecured debt and to shares already included in the company’s last shelf registration.

According to Moody’s:

Boston Scientific’s commitment to lower leverage and cost-cutting initiatives should provide it with sufficient cushion to withstand ongoing pressures in its core markets. Furthermore, patent litigation risk continues to wind down, as recent developments appear to weigh in Boston Scientific’s favor.

The ratings agency also viewed the appointment of a new president (soon to be CEO) as a positive development.

Contact [email protected] for any questions or corrections.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Top Gaining Stocks

SMCI Vol: 163,012,885
DELL Vol: 7,215,048
EQT
EQT Vol: 17,854,877
NRG Vol: 2,614,870

Top Losing Stocks

GEV Vol: 4,903,748
CTRA Vol: 73,319,495
NOW Vol: 43,600,909
PTC
PTC Vol: 2,206,283
WDAY Vol: 4,279,363